Recruiting Inflammatory Bowel Disease Studies in San Diego
A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3)
This study is designed to evaluate the long-term efficacy and safety of mirikizumab in participants with moderately to severely active ulcerative colitis (UC). The study will last up to 3 years. Parti...
Clinical, Imaging, and Endoscopic Outcomes of Children Newly Diagnosed With Crohn's Disease
Crohn's disease (CD) is a condition that causes inflammation (swelling, redness) of the lining and wall of the small intestine, large intestine, or both. CD may be associated with abdominal cramps/pai...
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease
This Phase III, multicenter, double-blind, placebo-controlled treat-through study will evaluate the efficacy and safety of induction and maintenance therapy with Afimkibart (also known as RO7790121) i...
A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab
Ulcerative colitis (UC) is a type of inflammatory bowel disease that causes inflammation and bleeding from the lining of the rectum and colon (large intestine).This study will evaluate how safe and ef...
Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease
Crohn's disease (CD) is a long-lasting disease that causes severe inflammation (redness, swelling), in the digestive tract, most frequently affecting the bowels. It can cause many different symptoms i...
A Study to Assess the Efficacy and Safety of Afimkibart (Also Known as RO7790121) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis
This Phase III, multicenter, double-blind, placebo-controlled, treat-through study will evaluate the efficacy and safety of Afimkibart (RO7790121) compared with placebo in participants with moderately...
A Study of Vedolizumab in Children With Ulcerative Colitis (UC) or Crohn's Disease (CD)
The study is an extension of two parent studies (MLN0002-3024 \[NCT04779307\] and MLN0002-3025 \[NCT04779320\]). Participants must have participated in one of the previous studies. The purpose of this...
Study of GS-1427 in Participants With Moderately to Severely Active Ulcerative Colitis
The goal of this study is to learn if GS-1427 is effective in treating participants with moderate to severe ulcerative colitis. The study will compare participants in different treatment groups treate...
Precise Infliximab Exposure and Pharmacodynamic Control
Approximately 3 million people in the United States are living with inflammatory bowel disease, which includes Crohn's Disease (CD). There are limited treatment options approved for use in children an...
A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Crohn's Disease (CD)
Vedolizumab is a medicine that helps to reduce inflammation and pain in the digestive system. In this study, children and teenagers with moderate to severe Crohn's disease will be treated with vedoliz...
A Study of Mirikizumab (LY3074828) in Pediatric Participants With Moderately to Severely or Active Ulcerative Colitis
The main purpose of this study is to investigate efficacy, pharmacokinetics and safety of the drug in pediatric participants with moderately to severely active ulcerative colitis (UC)....
Efficacy/Safety of ALTB-268 in Subjects w/Moderately to Severely Active UC Refractory to Biologics
ALTB-268-201 is a Phase 2a, multicenter, single arm, multiple-dose, open-label study evaluating the efficacy and safety of ALTB-268 in subjects with moderately to severely active UC. The study consist...
About Inflammatory Bowel Disease Clinical Trials in San Diego
Inflammatory bowel disease (IBD) encompasses chronic inflammatory conditions of the gastrointestinal tract, primarily Crohn's disease and ulcerative colitis. It affects millions worldwide and can cause debilitating symptoms. Treatment includes anti-inflammatory drugs, immunosuppressants, biologics, and surgery.
There are currently 12 inflammatory bowel disease clinical trials recruiting participants in San Diego, CALIFORNIA. These studies are seeking a combined 4,871 participants. Research is being sponsored by Eli Lilly and Company, Connecticut Children's Medical Center, Hoffmann-La Roche and 5 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.
Inflammatory Bowel Disease Clinical Trials in San Diego — FAQ
Are there inflammatory bowel disease clinical trials in San Diego?
Yes, there are 12 inflammatory bowel disease clinical trials currently recruiting in San Diego, CALIFORNIA. Browse the studies on this page to find one that fits.
How do I join a clinical trial in San Diego?
Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the San Diego research site will contact you about next steps.
Are clinical trials in San Diego free?
Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many San Diego studies also compensate for your time and travel.
What inflammatory bowel disease treatments are being tested?
The 12 active trials in San Diego are testing new therapies including novel drugs, biologics, and treatment approaches for inflammatory bowel disease.
Data updated March 2, 2026 from ClinicalTrials.gov